Owen Andrew
Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L693GF, UK; MRC Centre for Drug Safety Science, University of Liverpool, Liverpool, L69 3GE, UK; Tandem Nano Ltd., Foundation Building, 765 Brownlow Hill, Liverpool, L69 7ZX, UK.
Br J Pharmacol. 2014 Sep;171(17):3961-2. doi: 10.1111/bph.12820.
This article is part of a themed section on Nanomedicine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-17
本文是关于纳米医学主题板块的一部分。若要查看该板块中的其他文章,请访问http://dx.doi.org/10.1111/bph.2014.171.issue-17